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Abstract
Background: The inability of cancer cells to present antigen on the cell surface via MHC class I
molecules is one of the mechanisms by which tumor cells evade anti-tumor immunity. Alterations
of Jak-STAT components of interferon (IFN)-mediated signaling can contribute to the mechanism
of cell resistance to IFN, leading to lack of MHC class I inducibility. Hence, the identification of IFN-
γ-resistant tumors may have prognostic and/or therapeutic relevance. In the present study, we
investigated a mechanism of MHC class I inducibility in response to IFN-γ treatment in human
melanoma cell lines.
Methods: Basal and IFN-induced expression of HLA class I antigens was analyzed by means of
indirect immunofluorescence flow cytometry, Western Blot, RT-PCR, and quantitative real-time
RT-PCR (TaqMan® Gene Expression Assays). In demethylation studies cells were cultured with 5-
aza-2'-deoxycytidine. Electrophoretic Mobility Shift Assay (EMSA) was used to assay whether IRF-
1 promoter binding activity is induced in IFN-γ-treated cells.
Results: Altered IFN-γ mediated HLA-class I induction was observed in two melanoma cells lines
(ESTDAB-004 and ESTDAB-159) out of 57 studied, while treatment of these two cell lines with
IFN-α led to normal induction of HLA class I antigen expression. Examination of STAT-1 in
ESTDAB-004 after IFN-γ treatment demonstrated that the STAT-1 protein was expressed but not
phosphorylated. Interestingly, IFN-α treatment induced normal STAT-1 phosphorylation and HLA
class I expression. In contrast, the absence of response to IFN-γ in ESTDAB-159 was found to be
associated with alterations in downstream components of the IFN-γ signaling pathway.
Conclusion: We observed two distinct mechanisms of loss of IFN-γ inducibility of HLA class I
antigens in two melanoma cell lines. Our findings suggest that loss of HLA class I induction in
ESTDAB-004 cells results from a defect in the earliest steps of the IFN-γ signaling pathway due to
absence of STAT-1 tyrosine-phosphorylation, while absence of IFN-γ-mediated HLA class I
expression in ESTDAB-159 cells is due to epigenetic blocking of IFN-regulatory factor 1 (IRF-1)
transactivation.
Published: 23 February 2007
BMC Cancer 2007, 7:34 doi:10.1186/1471-2407-7-34
Received: 19 October 2006
Accepted: 23 February 2007
This article is available from: http://www.biomedcentral.com/1471-2407/7/34
© 2007 Rodríguez et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2007, 7:34 http://www.biomedcentral.com/1471-2407/7/34
Page 2 of 11
(page number not for citation purposes)
Background
Interferon gamma (IFN-γ) is a pro-inflammatory pleio-
tropic cytokine that plays a central role in promoting
innate and adaptive mechanisms of host defense [1,2].
Interferon IFN-γ secreted by T and natural killer (NK) cells
is important in driving T helper cell type 1 (Th1)
responses. In addition, IFN-γ plays a key role in providing
an immunocompetent host with a mechanism of tumor
surveillance [3]. Specific antitumor immune responses
require expression of MHC class I on tumor cells, and
MHC antigen down-regulation is a presumed tumor
growth promoting mechanism [4]. However, there is
experimental evidence of tumors showing dysregulation
of multiple signaling pathways that interfere with
cytokine signals [5,6]. Certain tumors may lose IFN-γ sen-
sitivity as a mechanism to evade immune detection [7].
IFNs exert their effects by binding cell surface receptors,
triggering an intracellular signaling cascade of Janus
kinases (Jak) and signal transducers and activators of tran-
scription (STAT) proteins, which results in the transcrip-
tion of IFN-inducible genes. IFN-γ exerts its effects after
binding to a receptor composed of two heterodimeric
receptor subunits, IFN-γ R1 and IFN-γ R2, which are intra-
cellularly associated with Janus kinases (Jaks) Jak-1 and
Jak-2, respectively [8,1]. The binding initiates receptor oli-
gomerization and phosphorylation of tyrosine residues in
Jak1, Jak2, and the cytoplasmic tail of IFN-γ R1. Each
phosphorylated IFN-γ R1 chain becomes a docking site for
STAT-1. After docking at the receptor, STAT-1 phosphor-
ylated on tyrosine 701 undergoes dimerization and trans-
locates to the nucleus, where it binds the IFN-γ activation
sequence (GAS) elements present in the promoters of
IFN-γ-inducible genes. IFN-γ is one of the strongest induc-
ers of IRF-1 via activation of STAT-1 and binding to the
GAS sequence within the IRF-1 promoter. In addition,
IFN-γ upregulated HLA class I expression via a STAT-1/
IRF1-dependent pathway. HLA class I promoter contains
the IFN-γ-responsive element (IRSE) [9], which is a bind-
ing site for factors of the IRF family and mediates the
induction of MHC class I transcription by IFNs. IFN-γ has
an additional rout, distinct from that of IFN-α, for upreg-
ulation of HLA class I via class II transactivator (CIITA)
that binds the α-site of HLA class I promoter [9]. Type-I-
IFN induced Jak-STAT signaling is propagated similarly to
IFN-g-induced Jak-STAT signaling. Activated TYK2 and
JAK1 phosphorylate STAT1 and STAT2. Type-I-IFN-medi-
ated signaling then induces homodimerization of STAT1
and heterodimerization of STAT1 and STAT2 (in case of
IFN-γ only dimerization of Stat1 takes place) which subse-
quently associate with the cytosolic transcription factor
IFN-regulatory factor 9 (IRF9), forming a trimeric com-
plex known as IFN-stimulated gene factor 3 (ISGF3). On
entering the nucleus, ISGF3 binds IFN-stimulate response
elements (ISREs) [10]. IFN-α-mediated MHC class I
induction involves two protein families, the STATs and
IRFs, which form the interferon-stimulated transcription
factor-3 (ISGF3) complex that also binds the IRSE
sequence.
Because immunotherapy is an important approach to
melanoma treatment, it is important to understand the
mechanisms by which these tumors circumvent IFN sign-
aling, thereby representing a potential mechanism of
melanoma cytokine-resistance to therapy. The aim of this
study was to evaluate the expression of HLA class I anti-
gens in response to IFN-γ in 57 human melanoma cell
lines. Defects in the inducibility of HLA class I antigens in
response to IFN-γ and normal response to IFN-α induc-
tion were observed in two of the tested melanoma cell
lines (ESTDAB-004 and ESTDAB-159).
Methods
Cell culture and reagents
Fifty seven melanoma cell lines were obtained from the
European Searchable Tumor Cell Line Data Base (ESTDAB
project, contract no.QLRI-CT-2001-01325) [11].
Melanoma cell lines were grown in RPMI medium (Bio-
chrom KG, Berlin, Germany) supplemented with 10%
fetal calf serum (FCS; Gibco BRL, Life Technologies, Karl-
sruhe, Germany), 2% glutamine (Biochrom KG, Berlin,
Germany), and 1% penicillin/streptomycin (Biochrom
KG, Berlin, Germany) at 37°C in a humidified atmos-
phere with 5% CO2. Cell lines were treated with IFN-γ or
IFN-α for 48 h. Recombinant IFN-γ and IFN-α were pur-
chased from R&D Systems (Minneapolis, USA). For
demethylation studies, cells were resuspended in fresh
complete medium (5 × 106cells/ml) and cultured with 3
μM of 5-aza-2'-deoxycytidine (Sigma-Aldrich, Madrid,
Spain) for 7 days.
Responsiveness of human tumor cells to IFN was assessed
after incubation of the cells in the presence of IFN-γ (800
IU/ml) or IFN-α (800 IU/ml) for 48 h followed by FACS
analysis of MHC class I antigen expression. PBS was used
as a control. Anti-IRF-1, and consensus IRF-1 gel shift oli-
gonucleotides were obtained from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA, USA). Monoclonal antibodies
against IRF-1 and STAT-1 were obtained from Transduc-
tion Laboratories (Lexington, KY, USA). Polyclonal anti-
body against phospho- STAT-1 at residue Tyr-701 was
obtained from Cell Signaling Technology (Beverly, MA,
USA). Rabbit anti-SOCS-1 polyclonal antibody (AnaSpec,
Inc, San Jose, CA, USA) and an anti-Phospho-Jak2
(Tyr1007/1008) antibody (Cell Signaling Technology,
USA) were also used.
HLA cell surface expression
Surface expression of HLA class I antigens was determined
by indirect immunofluorescence using a panel of mono-
clonal antibodies, W6/32 (HLA-ABC), L-362 (β2 m),BMC Cancer 2007, 7:34 http://www.biomedcentral.com/1471-2407/7/34
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1082C5 (HLA-A), Q6/64 (HLA-B), 126.39 (HLA-Bw6),
and 116-5-28 (HLA-Bw4). 105 cells were treated with IFN
at 800 IU/ml for 48 h. Cells were harvested using buffered
EDTA solution, then washed with RPMI medium contain-
ing 10% v/v FCS and 0.1% w/v sodium azide (medium/
FCS/azide) prior to incubation with primary antibody
(diluted in medium/FCS/azide) for 60 min at 4°C in the
dark. After incubation with unlabeled primary antibody,
the cells were washed, incubated with FITC-labeled sec-
ondary antibody for 45 min at 4°C, and then washed
again. Flow cytometry was performed using BD FACSort
(Becton Dickinson, Oxford, UK). Ten thousand events
were captured and analyzed using CellQuest software
(Becton Dickinson).
Western Blot Analysis
The melanoma cell lines were treated with IFN-α and IFN-
γ for different periods of time and cultured in medium
containing 0.5% FCS for 2 h before lysing with 1X SDS
sample buffer (62.5 mM Tris-HCl, 2% w/v SDS, 10% glyc-
erol, 50 mM DTT, 0.01% w/v bromophenol blue). Pro-
teins from the whole cell lysates were separated by
polyacrylamide gel electrophoresis and transferred to
nitrocellulose membranes, which were then sequentially
incubated in primary antibody overnight at 4°C and then
with HRP-conjugated secondary antibody (1:2000) in
blocking buffer for 1 h at room temperature. Protein
extracts from whole-cell lysates were probed for mono-
clonal antibodies that recognize STAT1 or phospho-Y701
STAT1 (Cell Signaling, Beverly, MA, USA). Before incubat-
ing with primary antibodies, membranes were placed in a
blocking buffer containing 1X TBS, 0.1% Tween-20 and
5% nonfat dry milk for 1 h at room temperature. The dilu-
tion buffer for the primary and secondary antibodies con-
tained 1XTBS, 0.1 Tween-20 and 5% BSA. For detection of
immunolabeled proteins, membranes were incubated
with 0.5 ml 20X LumiGLO and 0.5 ml 20X peroxide in 9
ml of water with gentle agitation for 1 min at room tem-
perature and then transferred to X-ray film. Anti-γ-tubulin
antibody was used to normalize the protein content in
each well of gel electrophoresis. As a positive control we
used the extract from cell line A549 that came as a part of
the anti-phospho-STAT1 antibody kit (Cell Signaling,
Beverly, MA, USA).
RNA isolation and RT-PCR
Total cellular RNA was isolated using a Qiagen RNeasy kit
(Qiagen GmbH, Hilden, Germany) according to the man-
ufacturer's instructions. Total RNA (0.5 μg) was subjected
to reverse transcription, and one-tenth of the reaction
mixture was used for PCR analysis. First strand cDNA was
synthesized with 10 μl of total RNA, using Sensiscript
reverse transcriptase kit (Quiagen) with 40 U/μl of RNasin
(Promega, Madison, WI, USA) and random primers
(Promega Madison, WI, USA) in a final volume of 20 μl.
The reaction was incubated at 42°C for 60 min and
stopped at 95°C for 5 min. Time-course effect of IFN-γ on
the mRNA expression of IRF-1, iNOS, and HLA-B in EST-
DAB-159 were measured. The following primer pairs were
used: 5- CGG CCT TAA GAA CCA GGC AAC CT-3 (for-
ward) and 5-CCA GCT TCT CTG CAC CAT ATC CA-3
(reverse), for differential expression of IRF-1 mRNAs; 5-
GAG CTT CTA CCT CAA GCT ATC-3 (forward) and 5-CCT
GAT GTT GCC ATT GTT GGT -3 (reverse) for iNOS
mRNA: and 5-GAC AGC GAC GCC GCG AGT CC -3 (for-
ward) and 5- AGT AGC GAC CAC AGC TCC GA-3
(reverse) for HLA-B mRNA. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as an internal control.
The primers for GAPDH were 5 -TGA AGG TCG GAG TCA
ACG GAT TTG GT-3 (forward) and 5 -CAT GTG GGC CAT
GAG GTC CAC CAC-3 (reverse).
Real-Time PCR
RT-PCR products were analyzed by quantitative real-time
RT-PCR in TaqMan® Gene Expression Assays of several tar-
get genes: HLA-A, HLA-B heavy chain, HLA-A (Hs
00740413-g1), HLA-B (Hs 00818803-g1), and beta glu-
curonidase (GUSB; as an endogenous control) (Applied
Biosystems; Foster City, CA, USA) for variations in the
amounts of RNA. All PCR reactions were performed in a
real time PCR 7500 system. Gene expression quantitation
using TaqMan® Gene Expression Assays was performed as
the second step in a two-step RT-PCR. Assays were done in
20-μL singleplex reactions containing TaqMan® Universal
PCR Master Mix, 20X TaqMan® Gene Expression Assay
Mix, and cDNA according the manufacturer's instructions
(Applied Biosystems). Reaction conditions consisted of
pre-incubation at 50°C for 2 min, 95°C for 10 min, then
cycling for 40 cycles of 95°C for 15 sec and 60°C for 1
min.
Electrophoretic Mobility Shift Assay
Nuclear extract was prepared as previously described
[12,13] in the presence of protease inhibitors. Extracts
were aliquoted and stored at -80°C. For each electro-
phoretic mobility shift assay reaction, 4 μg of nuclear pro-
teins were incubated with 30,000 cpm of [γ-32P]ATP-
labeled consensus IRF-1 gel shift oligonucleotide (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) for 30 min on
ice. In competition assay unlabeled IRF-1 consensus or
anti-IRF-1 monoclonal antibody (2 μg) of rabbit polyclo-
nal antisera against IRF-1 (Santa-Cruz Biotechnology,
USA) were incubated with nuclear extracts for 10 min on
ice prior to the addition of radiolabeled oligonucleotides.
Reaction mixtures were then separated on a 5% native
polyacrylamide gel. After electrophoresis, the gel was
dried and subjected to autoradiography.BMC Cancer 2007, 7:34 http://www.biomedcentral.com/1471-2407/7/34
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Results
Loss of IFN-γ-mediated MHC class I inducibility in 
melanoma cell lines
Cell surface expression of HLA class I molecules was ana-
lysed in a panel of 57 melanoma cell lines by flow cytom-
etry. The response of MHC class I expression to IFN-
treatment varied. Almost all of the melanoma cell lines
showed increased surface expression of HLA class I anti-
gens after 48 h of culture. Only four melanoma cell lines
did not increase MHC class I expression after incubation
with IFN-γ. Since two of them had β2 microglobulin
mutation [14], they were not included in this study. How-
ever, the other two lines (ESTDAB-004 and ESTDAB-159)
(Fig. 1) with absence of IFN-γ mediated increase in expres-
sion of the HLA class I molecules demonstrated HLA class
I induction after treatment with IFN-α. Loss of IFN-γ
mediated inducibility was also observed in MHC class II
molecules (not shown). MHC class I expression in these
two cell lines was also analysed by quantitative RT-PCR,
and no upregulation of MHC class I mRNA was detected
(Fig 1A). Treatment of both cell lines with 800 U/ml IFN-
γ for 48 h produced no significant increase in the expres-
sion of MHC class I mRNA in comparison with a control
cell line (ESTDAB-052, which responded with HLA-class I
induction) (Fig. 1A). This finding was consistent with the
protein expression as demonstrated by FACS analysis (Fig.
1B). Loss of IFN-γ mediated class I inducibility was not
caused by a post-transcriptional defect. Because the IFN-γ
signal transduction pathway shares two intracellular sig-
nalling molecules with the IFN-α pathway, these cells
were also tested for their ability to up-regulate MHC class
I in response to IFN-α. Both melanoma cell lines
responded to IFN-α treatment with an increased MHC
class I cell surface expression, indicating the possibility of
a specific and selective alteration only in the IFN-γ signal-
ling pathway.
IFN-γ resistant cell lines (ESTDAB-004 and ESTDAB-159) 
have different patterns of alteration in the IFN-γ signaling 
pathway
STAT-1 phosphorylation was examined by western blot
using anti-STAT-1 or anti -phospho-STAT-1 antibodies
that recognize unphosphorylated or phosphorylated
STAT-1, respectively. Cells were incubated with 800 U/ml
IFN-γ or IFN-α before western blot analysis. STAT-1 induc-
tion and activation were analyzed in both cell lines to
yield further information on the possible mechanism of
altered response to IFN-γ treatment. As shown in Figure 2,
STAT-1 tyrosine phosphorylation occurred only in the
ESTDAB-159 cells, whereas phosphorylation was unde-
tectable in ESTDAB-004 cells. STAT-1 phosphorylation
was upregulated and rapidly decreased after 60 min of
incubation with IFN-γ. However, both cell lines
responded with STAT-1 phosphorylation to IFN-α treat-
ment (Figure 2). The tyrosine phosphorylation of Jak-2 in
response to IFN-γ stimulation was also investigated.
Absence of phosphorylation in response to IFN-γ was
observed in ESTDAB-004 cells, which was correlated with
decreased IFN-γ signaling (Figure 3). Suppressor of
cytokine signaling-1 (SOCS1) is a critical negative regula-
tor of IFN-γ responses. Its expression is induced in
response to stimulation of a variety of cytokines, and over-
expression of this protein results in inhibition of cytokine
signaling [15]. SOCS1 protein expression was detected in
ESTDAB-004 melanoma cells without treatment with IFN-
γ and did not change after this treatment (Figure 3).
IRF-1 is upregulated in ESTDAB-159 cells in response to 
IFNγ
After tyrosine-phosphorylation, STATs form homo- or
heterodimers and translocate from the cytoplasm to the
nucleus, where they bind specific DNA sequences and
activate transcription of many genes. IRF-1 is transacti-
vated by binding of STAT-1 dimers to the GAS sequence of
the IRF-1 promoter. IRF-1 is the principal factor mediating
the IFN-γ-induced expression of MHC class I antigen. In
order to analyze the Jak-STAT signalling cascade, we inves-
tigated the induction of IRF-1 mRNA expression in
response to IFN-γ treatment. As shown in Figure 4A, IRF-1
mRNA was upregulated by IFN-γ treatment in ESTDAB-
159 cells. We also investigated the expression of another
IRF-1- regulated gene, iNOS, to determine whether MHC
class I gene expression is selectively blocked. We measured
iNOS mRNA level in IFN-γ-treated ESTDAB-159 cells. As
shown in Fig 4B, IFN-γ did not induce expression of iNOS
mRNA, indicating an inhibition of IRF-1 transactivated
genes.
IRF-1 binding activity is induced in INF-γ-treated ESTDAB-
159 cells
IFN-γ-stimulated IRF-1 induction was assayed using elec-
trophoretic mobility shift assay (EMSA). As shown in Fig.
5, IRF-1 binding to the consensus element was induced
after IFN-γ stimulation of ESTDAB-159 and of control cell
line ESTDAB-056. Protein complex formation between
IRF-1 and DNA probes was increased in the nuclear extract
of IFN-γ-treated melanoma cells (lanes 3, 4, 5 and 6). For-
mation of detectable complex was competed out with 50-
fold excess of unlabeled cold probe (lanes 1, 2). Supershift
experiments using an anti-IRF-1 antibody (lanes 7, 8)
indicated that the complex was specific. These results
strongly suggest that the nuclear protein complex that
binds to the putative IRF-1 binding probe contains a func-
tional IRF-1 protein.
5-Aza-2-deoxycytidine restores IFN-γ-mediated HLA-class 
I inducibility in ESTDAB-159 cells
We demonstrated the role of methylation in the loss of the
inducibility of HLA class I expression by incubating EST-
DAB-159 cells with the demethylating substance 5-Aza-2'-BMC Cancer 2007, 7:34 http://www.biomedcentral.com/1471-2407/7/34
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deoxycytidine. After 7 days of culture, 5-dAzaC restored
IFN-γ-induced HLA-class I expression. Treatment of cells
with either 5-dAzaC or IFN-γ alone did not lead to
increase (or only to a marginal increase) in HLA class I
protein or mRNA expression, respectively (Figure 6A).
Interestingly, administration of both 5-dAzaC and IFN-γ
produced an increase in the level of transcripts and led to
cell surface expression of HLA class I molecules, as
revealed by quantitative RT-PCR and flow cytometry anal-
ysis (Figure 6B).
Discussion
IFNs were the first cytokines to be used in clinical trials for
cancer treatment. IFNs have significant effects and play a
central role in providing an immunocompetent host with
a mechanism of tumor surveillance and in promoting
innate and adaptive host defense [3]. Moreover, IFN-γ
may have an anti-metabolic and inhibitory effect on
tumor cell growth in vitro, as has been shown in various
cell types, including malignant melanoma [16,17].
Importantly, for tumor rejection to occur, antigens must
be presented in a complex with HLA class I molecules on
the melanoma cell surface to be recognized by CTLs. In
this context, melanoma cells may attempt to escape cell-
mediated immunosurveillance in order to develop a per-
manent and selective IFN-γ insensitivity by inhibiting
expression of MHC molecules.
Many studies highlight the importance of Jak-STAT path-
ways in IFN resistance. Interestingly, melanomas differ in
their responsiveness to IFNs and can be IFN-sensitive or
IFN-resistant. IFN-resistant melanoma cells contain
reduced levels of ISGF3a components, particularly of
STAT-1, indicating that the non-responsiveness of
Transcription level (A) and cell surface expression (B) of HLA-ABC molecules in ESTDAB-004 and ESTDAB-159 melanoma  cell lines [in (B) examined by indirect immunofluorescence using W6/32 and L-362 mAb] Figure 1
Transcription level (A) and cell surface expression (B) of HLA-ABC molecules in ESTDAB-004 and ESTDAB-159 melanoma 
cell lines [in (B) examined by indirect immunofluorescence using W6/32 and L-362 mAb]. Cells were treated with 800 U/ml of 
either IFN-γ or IFN-α for 48 h or with culture medium alone. The dark histogram corresponds to the isotypic control. Panel A 
– the results of real-time RT-PCR analysis. On the Y-axis on panel A – mRNA copy number of the gene of interest (HLA-A or 
HLA-B) normalized against the mRNA copy number of the reference gene GUSB.
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melanoma cell lines to type I IFN may be due to a defi-
ciency in the expression of ISGF3 components [7]. An
absence of response to IFN in lung and prostate adenocar-
cinoma cell lines has been attributed to lack of Jak-1 gene
expression [18]. We also previously reported a deficiency
in STAT-1 component as a probable cause of resistance to
IFNs detected in a gastric carcinoma cell line [12,13]. In
the present report, our results suggest heterogeneity in the
mechanisms underlying IFN resistance in melanomas. We
analyzed MHC class I antigen inducibility after IFN-γ
treatment in 57 human melanoma cell lines. Only four
cell lines showed no responsiveness to IFN by flow cytom-
etry, and two of these were excluded from the study
because they presented a mutation in β2 m gene [19,14]
and recovered IFN-γ inducibility after reconstitution of
wild type β2 m gene (not shown). The remaining two cell
lines (ESTDAB-004 and ESTDAB-159) exhibited specific
resistance to IFN-γ but responded normally to IFN-α treat-
ment; the mechanism underlying IFN-γ resistance differed
between these two cell lines.
In ESTDAB-004 cells, our findings strongly suggest that
defective activation of STAT-1 was responsible for this
resistance. Thus, immunoblotting analysis of cell proteins
with antibodies against STAT-1 and phosphorylated
STAT-1 showed that ESTDAB-004 was not deficient in
STAT-1 proteins but that IFN-γ did not induce STAT1 tyro-
sine phosphorylation (Fig. 2). IFN-γ signaling pathway is
initiated upon binding of IFN-γ receptor. IFN-γ binds to
extracellular heterodimeric receptor subunits IFN-γ R1
The expression and the activation of STAT proteins Figure 2
The expression and the activation of STAT proteins. Cells were treated with IFN-γ or IFN-α at 800 IU/ml. Proteins from cellu-
lar protein extracts were separated by SDS-PAGE and transferred to nitrocellulose membrane. Western blotting was per-
formed as described in Materials and Methods. Anti-STAT1 and anti-phospho-STAT1 antibodies were used to assess STAT 
activation. Anti-γ-tubulin antibody was used to normalize the amounts of protein loaded in each well of the gel. Positive control 
(C+) of phosphorylated proteins from cellular extract A549 was obtained from Cell Signaling Technology.
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and IFN-γ R2, which are intracellularly associated with
Jak-1 and Jak-2, respectively [1,8]. This binding initiates
phosphorylation of tyrosine residues in Jak-1, Jak-2, and
the cytoplasmic tail of IFN-γ R1. Analysis of the IFN-γ
receptors revealed a similar expression in both of the
unresponsive cell lines (not shown). Importantly,
whereas IFN-α activates Jak-1 and Tyk2, IFN-γ activates
Jak-1 and Jak-2. Therefore, we only investigated the phos-
phorylation of Jak-2, because this kinase is not shared by
the IFN-α Jak-STAT pathway. ESTDAB-004 cells expressed
Jak-2 protein, but it was only marginally phosphorylated
in response to IFN-γ. SOCS1 induction by IFN-γ and neg-
ative regulation of IFN-γ signaling have been well docu-
mented [20,21]. Moreover, SOCS1 is aberrantly expressed
in melanoma cells [22]. Our findings confirm the consti-
tutive expression of SOCS1 protein in ESTDAB-004 cells
(Figure 3). We hypothesize that absence of STAT-1 phos-
phorylation in ESTDAB-004 cells may be mediated via
kinase inhibition of Jak-2 by the action of SOCS1 phos-
phatase.
In contrast, INF-γ treatment increased tyrosine phosphor-
ylation (activation) levels of STAT-1 in ESTDAB-159, the
other INF-γ resistant responsive cell line. IRF-1 was also
increased, indicating that homodimeric phosphorylated
STAT-1 complex is translocated to the nucleus and bound
to the GAS sequences in the IRF-1 promoter (Fig 4A).
Notably, treatment with IFN-γ produced higher IRF-1
mRNA levels with respect to ESTDAB-056, a melanoma
cell line with normal inducibility of MHC class I antigen
used as a control. However, none of the IRF-1 associated
target genes tested (MHC-class I and iNOS) were induced
by IFN-γ in ESTDAB-159 cells.
Pretreatment with all-trans-retinoic acid (atRA) was
reported to affect the transcriptional functions of IFN-γ
induced IRF-1, inducing its nuclear translocation and
enhancing DNA binding activity and transcript levels of
IRF-1 target genes [23]. Treatment of ESTDAB-159 cells
with atRA did not recover MHC class I inducibility (data
not shown). Importantly, point mutation of IRF-1 can
abolish IRF-1 DNA binding activity [24]. In acute myeloid
leukemia, point mutations or deletions of the IRF-1 gene
have frequently been detected [25]. Furthermore, loss of
heterozygosity in IRF-1 appears to be critical for the devel-
opment of human gastric cancers [26,27]. However, this
possibility of IRF-1 mutation or transcriptional factor
defects was ruled out in the ESTDAB-159 cells. Thus, IFN-
γ-induced nuclear translocation and DNA-binding activity
of IRF-1 was similar between ESTDAB-159 and control
cell line (ESTDAB-056) in an EMSA assay (Fig 5). In addi-
tion, sequencing of the complete IRF-1 cDNA revealed no
mutation (data not shown).
Available evidence suggests that IRF-1 may function as a
tumor-suppressor gene and might induce apoptosis medi-
ated via up-regulation of caspase 8 [28], a key mediator
frequently inactivated by epigenetic silencing in many
tumors by gene hypermethylation [29,30]. Here, we
report that treatment with 5-dAzaC helped to restore IFN-
γ-mediated HLA class I inducibility in ESTDAB-159 cells
(Fig. 6). We previously reported an epigenetic down-regu-
lation of HLA class I antigens in a melanoma cell line
MSR-3, which has hypermethylation of HLA class I genes
[31]. However, the MSR-3 cell line did not respond to
either IFN α or -γ and exhibited a complete absence of
HLA class I expression. The molecular basis of 5-dAzaC
activity is different in ESTDAB-159 for several possible
Western blot analysis of the expression level and phosphor- ylation status of Jak-2 (A), and of the expression of SOCS-1  (B) in ESTDAB-004 cell line Figure 3
Western blot analysis of the expression level and phosphor-
ylation status of Jak-2 (A), and of the expression of SOCS-1 
(B) in ESTDAB-004 cell line. We observed that Jak-2 was 
present but its phosphorylation was very low and was 
accompanied by a high SOCS-1 expression (negative regula-
tor of IFN-γ response). Arrows indicate the specific proteins. 
Nuclear extracts as a positive control (C+) for Jak-2 were 
obtained from Cell Signaling.
Jak2-P 
Jak2 
SOCS-1 
γ-tubulin
0’ 15’ 30’ 60’ C+
0’ 15’ 30’ 60’
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0’ 15’ 30’ 60’
15’ 30’ 60’ 0’
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reasons. Since ESTDAB-159 cells responded to IFN-α but
not to IFN-γ, it is possible that methylation affects the
binding of IRF-1 to the ISRE consensus motif in a higher
degree than the binding of ISFGF3 induced by IFN-α.
Another possibility is that the transactivation of IRF-1 is
inhibited by a dominant negative action of several factors
[32], which must be regulated by methylation. However
these possibilities need to be further investigated.
It summary, IFN-γ exposure in the cancer microenviron-
ment can create conditions for cancer cells to develop
alteration in IFN signaling and thereby provide these cells
with an adaptive mechanism to survive in hosts with com-
petent immune systems [18]. While IFN-α is used in treat-
ment of cancer with measurable efficacy [33], IFN-γ
demonstrated limited success in cancer immunotherapy
in humans. It might be explained by tumour-cell insensi-
tivity to IFN-γ [34], or an inability to therapeutically reca-
pitulate the natural periodicity of IFN-γ production. An
understanding of the mechanisms by which tumors cir-
cumvent cytokine signaling would greatly aid prediction
of the immune response in patients treated with IFNs.
Conclusion
We observed IFN-gamma mediated MHC class I induction
in the majority of the melanoma cell lines studied. How-
ever, in two cell lines we found different alterations in the
IFN-γ signalling pathway. In ESTDAB-004 cells the
absence to IFN-γ response was found to be associated with
a defect in the earliest steps of the IFN-γ signaling pathway
due to absence of STAT-1 tyrosine-phosphorylation. Con-
stitutive SOCS-1 expression may be partially responsible
for that. In another cell line, ESTDAB -159, the absence of
IFN-γ mediated HLA class I expression might be due to
epigenetic blocking of IRF-1 transactivation.
Time course effect of IFN-γ on the expression of IRF-1 and iNOS (A) Figure 4
Time course effect of IFN-γ on the expression of IRF-1 and iNOS (A). Total RNAs were isolated from ESTDAB-159 cell line 
and form the control cell line ESTDAB-056 grown in the presence or absence of 800 U/ml IFN-γ for the indicated periods of 
time and analyzed for the relative levels of mRNA by RT-PCR.
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EMSA showing the binding of IRF-1 to a 32P labeled probe containing the IRF-1 consensus sequence Figure 5
EMSA showing the binding of IRF-1 to a 32P labeled probe containing the IRF-1 consensus sequence. EMSA was performed with 
nuclear extracts obtained from untreated ESTDAB-056 (3) and ESTDAB-159 (5) melanoma cells or treated with 800 U/ml 
IFN-γ for 4 h (lanes 1, 4 and 7 corresponding to ESTDAB-056; and lanes 2, 6 and 8 corresponding to ESTDAB-159). A 50-fold 
molar excess of unlabeled IRF-1 probe was added to the binding reaction (lane 1, 2) to compete out the formation of a detect-
able complex. Anti-IRF-1 antibody was used to block IRF-1 binding to test the specificity of the interaction (lanes 7 and 8). 
Results shown are representative of at least three independent experiments.
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